Healthcare [ 13/13 ] | Diagnostics & Research [ 77/164 ]
NASDAQ | Common Stock
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States.
The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test.
It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
The company was founded in 2008 and is based in Mainz, Germany.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | 0.00 Increased by +100.00% | -0.25 Increased by +100.00% |
| Mar 6, 24 | 0.00 Increased by +100.00% | -0.32 Increased by +100.00% |
| Nov 16, 23 | -0.39 Increased by +9.30% | -0.47 Increased by +17.02% |
| Aug 15, 23 | -0.56 Decreased by -21.74% | -0.42 Decreased by -33.33% |
| Apr 27, 23 | -0.45 Increased by +46.43% | -0.46 Increased by +2.17% |
| Mar 8, 23 | -0.46 Decreased by -1.43 K% | -0.46 |
| Nov 2, 22 | -0.43 Decreased by -2.05 K% | -0.43 |
| Sep 7, 22 | -0.46 Decreased by -283.97% | -0.49 Increased by +6.12% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 181.67 K Increased by +87.69% | -6.30 M Decreased by -12.57% | Decreased by -3.47 K% Increased by +40.02% |
| Jun 30, 23 | 248.94 K Increased by +78.79% | -8.25 M Decreased by -18.92% | Decreased by -3.31 K% Increased by +33.48% |
| Mar 31, 23 | 193.28 K Increased by +20.77% | -8.19 M Increased by +28.35% | Decreased by -4.24 K% Increased by +40.67% |
| Dec 31, 22 | 144.34 K Increased by 0.00% | -2.92 M Increased by +2.86% | Decreased by -2.02 K% Increased by +2.86% |
| Sep 30, 22 | 96.79 K Decreased by -32.94% | -5.60 M Decreased by -91.49% | Decreased by -5.78 K% Decreased by -185.55% |
| Jun 30, 22 | 139.24 K Decreased by -66.63% | -6.94 M Decreased by -2.78 K% | Decreased by -4.98 K% Decreased by -8.54 K% |
| Mar 31, 22 | 160.04 K Increased by +10.88% | -11.43 M Decreased by -28.48 K% | Decreased by -7.14 K% Decreased by -25.67 K% |
| Dec 31, 21 | 144.34 K Increased by +16.98% | -3.01 M Decreased by -1.95 K% | Decreased by -2.08 K% Decreased by -1.65 K% |